MOLN Stock Overview
A clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Molecular Partners AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF3.78 |
| 52 Week High | CHF7.32 |
| 52 Week Low | CHF3.32 |
| Beta | 0.80 |
| 1 Month Change | 13.86% |
| 3 Month Change | -18.80% |
| 1 Year Change | -42.99% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -80.76% |
Recent News & Updates
Shareholder Returns
| MOLN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.5% | 3.2% | 1.7% |
| 1Y | -43.0% | 6.0% | 26.3% |
Return vs Industry: MOLN underperformed the US Biotechs industry which returned 6% over the past year.
Return vs Market: MOLN underperformed the US Market which returned 26.3% over the past year.
Price Volatility
| MOLN volatility | |
|---|---|
| MOLN Average Weekly Movement | 11.6% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: MOLN has not had significant price volatility in the past 3 months.
Volatility Over Time: MOLN's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 168 | Patrick Amstutz | www.molecularpartners.com |
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors.
Molecular Partners AG Fundamentals Summary
| MOLN fundamental statistics | |
|---|---|
| Market cap | US$120.75m |
| Earnings (TTM) | -US$64.45m |
| Revenue (TTM) | US$7.41m |
16.3x
P/S Ratio-1.9x
P/E RatioIs MOLN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MOLN income statement (TTM) | |
|---|---|
| Revenue | CHF6.73m |
| Cost of Revenue | CHF47.84m |
| Gross Profit | -CHF41.12m |
| Other Expenses | CHF17.41m |
| Earnings | -CHF58.53m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 26, 2024
| Earnings per share (EPS) | -1.76 |
| Gross Margin | -611.33% |
| Net Profit Margin | -870.22% |
| Debt/Equity Ratio | 0% |
How did MOLN perform over the long term?
See historical performance and comparison